Instead, we suggest that screening for the RET mutation testing for hereditary MTC ought to be implemented into existing state newborn screening programs and treated similarly to other newborn screening tests, which include the screening for hypothyroidism. This evidence concerns the gene RET and medullary thyroid gland carcinoma.